| Platinum-Resistant Primary Peritoneal Carcinoma studied in …STUDIED_INderived10 of 31show all (up to 200) |
|---|
| → studied in | NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026062Phase 2 · completed Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113487Phase 2 · active not recruiting P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05465941Phase 2 · active not recruiting PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02650986Phase 1/Phase 2 · active not recruiting Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587311Phase 2 · active not recruiting Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538091Phase 2 · recruiting Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |